揭示免疫抑制树突状细胞在胰腺癌中的作用

Annals of Pancreatic Cancer Pub Date : 2018-09-01 DOI:10.21037/APC.2018.09.02

D. Thomas, A. Murphy

{"title":"揭示免疫抑制树突状细胞在胰腺癌中的作用","authors":"D. Thomas, A. Murphy","doi":"10.21037/APC.2018.09.02","DOIUrl":null,"url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a debilitating disease that continues to have rising incidence and mortality rates. In 2018, it is estimated that nearly 56,000 individuals will be newly diagnosed with pancreatic cancer (1). Surgical resection remains the only possible curative measure as pancreatic cancer is notoriously resistant to systemic chemotherapy, has high rates of recurrence, and is associated with a 5-year survival rate of 8.5 (1).","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Uncovering the role of immunosuppressive dendritic cells in pancreatic cancer\",\"authors\":\"D. Thomas, A. Murphy\",\"doi\":\"10.21037/APC.2018.09.02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pancreatic ductal adenocarcinoma (PDAC) is a debilitating disease that continues to have rising incidence and mortality rates. In 2018, it is estimated that nearly 56,000 individuals will be newly diagnosed with pancreatic cancer (1). Surgical resection remains the only possible curative measure as pancreatic cancer is notoriously resistant to systemic chemotherapy, has high rates of recurrence, and is associated with a 5-year survival rate of 8.5 (1).\",\"PeriodicalId\":8372,\"journal\":{\"name\":\"Annals of Pancreatic Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Pancreatic Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21037/APC.2018.09.02\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Pancreatic Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/APC.2018.09.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

胰腺导管腺癌(PDAC)是一种使人衰弱的疾病，发病率和死亡率持续上升。据估计，2018年将有近56,000人被新诊断为胰腺癌(1)。手术切除仍然是唯一可能的治疗措施，因为胰腺癌对全身化疗具有耐药性，复发率高，5年生存率为8.5(1)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Uncovering the role of immunosuppressive dendritic cells in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a debilitating disease that continues to have rising incidence and mortality rates. In 2018, it is estimated that nearly 56,000 individuals will be newly diagnosed with pancreatic cancer (1). Surgical resection remains the only possible curative measure as pancreatic cancer is notoriously resistant to systemic chemotherapy, has high rates of recurrence, and is associated with a 5-year survival rate of 8.5 (1).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Pancreatic Cancer

CiteScore

0.90

自引率

0.00%

发文量